Loading...
Management of splanchnic vein thrombosis (SVT), which includes portal, mesenteric, splenic, and hepatic vein thrombosis, is heterogenous, given a lack of randomized clinical trials (RCTs). To evaluate the efficacy and safety of anticoagulation in patients with SVT, investigators performed a meta-analysis of individual patient data. Measures of efficacy included recurrent venous thrombosis and all-cause mortality; measures of safety included major bleeding.
A total of 1635 patients from three studies (no RCTs) were analyzed. The most common causes for SVT included solid tumors (32.0%), cirrhosis (17.6%), and myeloproliferative neoplasms (7.2%). SVT was unprovoked in 28.3% of cases. Eighty percent of patients were treated with anticoagulation,…